RE:RE:RE:RE:To better understand the complexity of ADCsFrom the same article again. On the importance for Thera to developp asap their peptide coupled with Ga68. It is a common thing in this field an easy to do. Look.
More than 200 reports were published focusing on the investigation of various Bn-like peptides conjugated primarily with radionuclides, including 9mTc, 111In, 67Ga, 68Ga, 64Cu, 177Lu, 90Y or 213Bi, which were either used for tumor diagnostic or peptide receptor radionuclide therapy (PRRT) (Dash et al., 2015).
A number of these studies reported excellent visualization of BnR overexpressing tumors like prostate cancer in vivo as well as in humans (Scopinaro et al., 2002, 2004; van Essen et al., 2009).
jfm1330 wrote: Now a critical aspect that I pointed to many times here and maybe the greatest weakness in Thera's approach as far as I know. This is critical to have a chance to acieve success. That is why I talk so often about the imaging possibility with radioisotopes like Ga68.
Peptide Receptors as Targets in Cancer Therapy
A major challenge in the development of novel and highly effective anti-cancer drugs is the selective drug-delivery to the tumor site while healthy tissue is spared. Cell surface receptors are of high interest in the targeted cancer therapy approach as they provide the desired properties to allow selective tumor targeting () (Reubi, 2003; Vhora et al., 2014). One of these requirements is the ectopical overexpression in high amounts on the malignant tissue to facilitate a sufficient selectivity. A tumor-to-normal-cell expression ratio of 3:1 or higher is usually desired. Secondly, the amounts of overexpressed receptors have to be sufficient to ensure drug delivery in appropriate amounts to obtain the desired therapeutic effect (Reubi, 2003; Vrettos et al., 2018). The determination of these expression levels is not trivial since tissue sampling and processing is difficult to standardize. Expression levels can vary not only within biopsies, but also over the time course of the therapy and therefore each treatment plan has to be tailored for every patient.